Evidence map›Paper›PMID 26857456›Full record

ArticleBreast cancer research : BCR2016

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.

Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, Susan L Neuhausen, Stephen Fox, Beth Y Karlan, Gillian Mitchell, Paul James, Darcy L Thull, Kristin K Zorn and 139 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 117 citations in OpenAlex.

  1. The Oncotype DX® 21-gene recurrence score and clinical outcomes in hormone receptor-positive, HER2-negative male breast cancer: a scoping review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. GermlinePathology oncology research : POR · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Cancers · 2023
    Article
  15. Article
  16. Molecular characteristics of Asian male BRCA-related cancers.Breast cancer research and treatment · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

149 authors at 20 institutions in 27 countries.

Valentina SilvestriDepartment of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. valentina.silvestri@uniroma1.it.
Daniel BarrowdaleCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. daniel@srl.cam.ac.uk.
Anna Marie MulliganLaboratory Medicine Program, University Health Network, Toronto, ON, Canada. annamarie.mulligan@uhn.ca.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. sneuhausen@coh.org.
Stephen FoxPeter MacCallum Cancer Institute, East Melbourne, Australia. stephen.fox@petermac.org.
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. beth.karlan@cshs.org.
Gillian MitchellFamilial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia. gillian.mitchell@petermac.org.
Paul JamesFamilial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia. paul.james@petermac.org.
Darcy L ThullUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dthull@magee.edu.
Kristin K ZornUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, USA. kkzorn@uams.edu.
Natalie J CarterUPMC Cancer Center, Pittsburgh, PA, USA. engeln@upmc.edu.
Katherine L NathansonDepartment of Medicine, Abramson Cancer Center, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA. knathans@exchange.upenn.edu.
Susan M DomchekDepartment of Medicine, Abramson Cancer Center, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA. susan.domchek@uphs.upenn.edu.
Timothy R RebbeckDepartment of Epidemiology and Biostatistics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. rebbeck@exchange.upenn.edu.
Susan J RamusDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA. sramus@usc.edu.
Robert L NussbaumDepartment of Medicine and Genetics, University of California, San Francisco, San Francisco, CA, USA. nussbaumr@humgen.ucsf.edu.
Olufunmilayo I OlopadeCenter for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, IL, USA. folopade@medicine.bsd.uchicago.edu.
Johanna RantalaDepartment of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. johanna.rantala@karolinska.se.
Sook-Yee YoonCancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia. sookyee.yoon@carif.com.my.
Maria A CaligoSection of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy. adelaide.caligo@do.unipi.it.
Laura SpugnesiSection of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy. laura.spugnesi@gmail.com.
Anders BojesenDepartment of Clinical Genetics, Vejle Hospital, Vejle, Denmark. anders.bojesen@slb.regionsyddanmark.dk.
Inge Sokilde PedersenSection of Molecular Diagnostics, Department of Biochemistry, Aalborg University Hospital, Aalborg, Denmark. isp@rn.dk.
Mads ThomassenDepartment of Clinical Genetics, Odense University Hospital, Odense C, Denmark. mads.thomassen@rsyd.dk.
Uffe Birk JensenDepartment of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark. uffejens@rm.dk.
Amanda Ewart TolandDepartment of Molecular Virology, Immunology and Medical Genetics, College of Medicine, The Ohio State University, Columbus, OH, USA. amanda.toland@osumc.edu.
Leigha SenterDivision of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. leigha.senter@osumc.edu.
Irene L AndrulisDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. andrulis@lunenfeld.ca.
Gord GlendonLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. gord.glendon@cancercare.on.ca.
Peter J HulickCenter for Medical Genetics, North Shore University Health System, Evanston, IL, USA. phulick@northshore.org.
Evgeny N ImyanitovN.N. Petrov Institute of Oncology, St. Petersburg, Russia. evgeny@imyanitov.spb.ru.
Mark H GreeneClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. greenem@mail.nih.gov.
Phuong L MaiClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. maip@mail.nih.gov.
Christian F SingerDepartment of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. christian.singer@meduniwien.ac.at.
Christine Rappaport-FuerhauserDepartment of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. christine.rappaport@akhwien.at.
Gero KramerDepartment of Urology, Medical University of Vienna, Vienna, Austria. gero.kramer@meduniwien.ac.at.
Joseph VijaiDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. josephv@mskcc.org.
Kenneth OffitDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. offitk@mskcc.org.
Mark RobsonClinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. robsonm@mskcc.org.
Anne LincolnDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. lincolna@mskcc.org.
Lauren JacobsDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. jacobsl@mskcc.org.
Eva MachackovaDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. emachack@mou.cz.
Lenka ForetovaMasaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic. foretova@mou.cz.
Marie NavratilovaDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. mnavrati@mou.cz.
Petra VasickovaDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. vasickova@mou.cz.
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. couch.fergus@mayo.edu.
Emily HallbergDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. hallberg.emily@mayo.edu.
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, MN, USA. ruddy.kathryn@mayo.edu.
Priyanka SharmaDepartment of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA. psharma2@kumc.edu.
Sung-Won KimDepartment of Surgery, Daerim St. Mary's Hospital, Seoul, Korea. brcakorea@gmail.com.
kConFab Investigators
Manuel R TeixeiraDepartment of Genetics, Portuguese Institute of Oncology, Porto, Portugal. manuel.teixeira@ipoporto.min-saude.pt.
Pedro PintoDepartment of Genetics, Portuguese Institute of Oncology, Porto, Portugal. pedro.pinto@ipoporto.min-saude.pt.
Marco MontagnaImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS (Scientific Institute of Hospitalization and Care), Padua, Italy. montagna@unipd.it.
Laura MatricardiImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS (Scientific Institute of Hospitalization and Care), Padua, Italy. laura.matricardi@ioveneto.it.
Adalgeir ArasonDepartment of Pathology, Landspitali University Hospital and Biomedical Centre (BMC), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. adalgeir@landspitali.is.
Oskar Th JohannssonDepartment of Oncology, Landspitali University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland. oskarjoh@landspitali.is.
Rosa B BarkardottirDepartment of Pathology, Landspitali University Hospital and Biomedical Centre (BMC), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. rosa@landspitali.is.
Anna JakubowskaDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. aniaj@pum.edu.pl.
Jan LubinskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. lubinski@pum.edu.pl.
Angel IzquierdoGenetic Counseling Unit, Hereditary Cancer Program, Biomedical Research Institute of Girona (IDIBGI), Catalan Institute of Oncology, Girona, Spain. aizquierdo@iconcologia.net.
Miguel Angel PujanaBreast Cancer and Systems Biology Unit, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Barcelona, Spain. mapujana@iconcologia.net.
Judith BalmañaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. jbalmana@vhebron.net.
Orland DiezOncogenetics Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and Universitat Autònoma de Barcelona, Barcelona, Spain. odiez@vhebron.net.
Gabriella IvadyDepartment of Pathology, National Institute of Oncology, Budapest, Hungary. ivadygabi@oncol.hu.
Janos PappDepartment of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. janos.papp@oncol.hu.
Edith OlahDepartment of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. e.olah@oncol.hu.
Ava KwongThe Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, China. akwong@asiabreastregistry.com.
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
Heli NevanlinnaDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. heli.nevanlinna@hus.fi.
Kristiina AittomäkiDepartment of Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. kristiina.aittomaki@hus.fi.
Pedro Perez SeguraDepartment of Oncology, San Carlos Clinical Hospital Health Research Institute (IdISSC), San Carlos Clinical Hospital, Madrid, Spain. pperez.hcsc@salud.madrid.org.
Trinidad CaldesMolecular Oncology Laboratory, San Carlos Clinical Hospital Health Research Institute (IdISSC), San Carlos Clinical Hospital, Madrid, Spain. trinidad.caldes@salud.madrid.org.
Tom Van MaerkenCenter for Medical Genetics, Ghent University, Ghent, Belgium. tom.vanmaerken@ugent.be.
Bruce PoppeCenter for Medical Genetics, Ghent University, Ghent, Belgium. bruce.poppe@ugent.be.
Kathleen B M ClaesCenter for Medical Genetics, Ghent University, Ghent, Belgium. Kathleen.Claes@UGent.be.
Claudine IsaacsLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. isaacsc@georgetown.edu.
Camille ElanDepartment of Tumour Biology, Institut Curie, Paris, France. camille.elan@curie.net.
Christine LassetCNRS UMR5558, Université Lyon 1, Lyon, France. christine.lasset@lyon.unicancer.fr.
Dominique Stoppa-LyonnetDepartment of Tumour Biology, Institut Curie, Paris, France. dominique.stoppa-lyonnet@curie.net.
Laure BarjhouxINSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université Lyon, Lyon, France. laure.barjhoux@lyon.unicancer.fr.
Muriel BelottiDepartment of Tumour Biology, Institut Curie, Paris, France. muriel.belotti@curie.net.
Alfons MeindlDepartment of Gynaecology and Obstetrics, Technical University of Munich, Munich, Germany. alfons.meindl@lrz.tu-muenchen.de.
Andrea GehrigInstitute of Human Genetics, University of Wurzburg, Wurzburg, Germany. gehrig@biozentrum.uni-wuerzburg.de.
Christian SutterInstitute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany. c.sutter@med.uni-heidelberg.de.
Christoph EngelInstitute for Medical Informatics, Statistics and Epidemiology University of Leipzig, Leipzig, Germany. christoph.engel@imise.uni-leipzig.de.
Dieter NiederacherUniversity of Dusseldorf, Dusseldorf, Germany. niederac@uni-duesseldorf.de.
Doris SteinemannHannover Medical School, Hannover, Germany. steinemann.doris@mh-hannover.de.
Eric HahnenCenter for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany. eric.hahnen@uk-koeln.de.
Karin KastDepartment of Gynecology and Obstetrics, Technical University of Dresden, Dresden, Germany. karin.kast@uniklinikum-dresden.de.
Norbert ArnoldDepartment of Gynaecolgy and Obstetrics, University Hospital of Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany. norbert.arnold@uksh.de.
Raymonda Varon-MateevaInstitute of Human Genetics, Charité, Berlin, Germany. raymonda.varon-mateeva@charite.de.
Dorothea WandInstitute of Human Genetics, Leipzig, Germany. dorothea.wand@medizin.uni-leipzig.de.
Andrew K GodwinDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA. agodwin@kumc.edu.
D Gareth EvansGenetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. gareth.evans@cmft.nhs.uk.
Debra FrostCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. djsf2@medschl.cam.ac.uk.
Jo PerkinsCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. jp410@medschl.cam.ac.uk.
Julian AdlardYorkshire Regional Genetics Service, Leeds, UK. julian.adlard@leedsth.nhs.uk.
Louise IzattClinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, UK. louise.izatt@gstt.nhs.uk.
Radka PlatteOncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. rp356@medschl.cam.ac.uk.
Ros EelesMolecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. rosalind.eeles@icr.ac.uk.
Steve EllisCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. steve@srl.cam.ac.uk.
EMBRACE
Ute HamannMolecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. u.hamann@dkfz-heidelberg.de.
Judy GarberCancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA. judy_garber@dfci.harvard.edu.
Florentia FostiraMolecular Diagnostics Laboratory, Institute of Nuclear and Radiological Sciences and Technology (INRASTES), National Centre for Scientific Research "Demokritos", Aghia Paraskevi Attikis, Athens, Greece. florentia@rrp.demokritos.gr.
George FountzilasDepartment of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. fountzil@auth.gr.
Barbara PasiniDepartment of Medical Science, University of Turin, Turin, Italy. barbara.pasini@unito.it.
Giuseppe GianniniDepartment of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. giuseppe.giannini@uniroma1.it.
Piera RizzoloDepartment of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. piera.rizzolo@uniroma1.it.
Antonio RussoSection of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy. lab-oncobiologia@usa.net.
Laura CortesiDepartment of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy. hbc@unimore.it.
Laura PapiUnit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. laura.papi@unifi.it.
Liliana VarescoUnit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, IRCCS (Scientific Institute of Hospitalization and Care), AOU San Martino - IST National Institute for Cancer Research, Genoa, Italy. liliana.varesco@hsanmartino.it.
Domenico PalliMolecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. d.palli@ispo.toscana.it.
Ines ZannaMolecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. i.zanna@ispo.toscana.it.
Antonella SavareseUnit of Genetic Counselling, Medical Oncology Department, Regina Elena National Cancer Institute, Rome, Italy. savarese@ifo.it.
Paolo RadiceUnit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), 20133, Milan, Italy. paolo.radice@istitutotumori.mi.it.
Siranoush ManoukianUnit of Medical Genetics, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), Milan, Italy. siranoush.manoukian@istitutotumori.mi.it.
Bernard PeisselUnit of Medical Genetics, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), Milan, Italy. bernard.peissel@istitutotumori.mi.it.
Monica BarileDivision of Cancer Prevention and Genetics, European Institute of Oncology (IEO), Milan, Italy. monica.barile@ieo.it.
Bernardo BonanniDivision of Cancer Prevention and Genetics, European Institute of Oncology (IEO), Milan, Italy. bernardo.bonanni@ieo.it.
Alessandra VielDivision of Experimental Oncology, CRO Aviano National Cancer Institute, Aviano, PN, Italy. aviel@cro.it.
Valeria PensottiIFOM, FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy. valeria.pensotti@ifom.eu.
Stefania TommasiNational Cancer Institute "Giovanni Paolo II", Bari, Italy. s.tommasi@oncologico.bari.it.
Paolo PeterlongoIFOM, FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy. paolo.peterlongo@ifom.eu.
Jeffrey N WeitzelClinical Cancer Genetics, City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA. jweitzel@coh.org.
Ana OsorioHuman Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain. aosorio@cnio.es.
Javier BenitezBiomedical Network on Rare Diseases (CIBERER), Madrid, Spain. jbenitez@cnio.es.
Lesley McGuffogCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. lesley@srl.cam.ac.uk.
Sue HealeyCancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia. sue.healey@qimrberghofer.edu.au.
Anne-Marie GerdesDepartment of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. anne-marie.gerdes@regionh.dk.
Bent EjlertsenDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. bent.ejlertsen@regionh.dk.
Thomas V O HansenCenter for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. tvoh@rh.dk.
Linda SteeleDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. lsteele@coh.org.
Yuan Chun DingDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. ycding@coh.org.
Nadine TungDepartment of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. ntung@bidmc.harvard.edu.
Ramunas JanaviciusState Research Institute Centre for Innovative Medicine, Vilnius, Lithuania. ramunas.janavicius@santa.lt.
David E GoldgarDepartment of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. david.goldgar@hsc.utah.edu.
Saundra S BuysDepartment of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. saundra.buys@hci.utah.edu.
Mary B DalyDepartment of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA. mary.daly@fccc.edu.
Anita BaneDepartment of Pathology & Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada. bane@hhsc.ca.
Mary Beth TerryDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. mt146@cumc.columbia.edu.
Esther M JohnDepartment of Epidemiology, Cancer Prevention Institute of California, Fremont, CA, USA. esther.john@cpic.org.
Melissa SoutheyGenetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Australia. msouthey@unimelb.edu.au.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. douglas@srl.cam.ac.uk.
Georgia Chenevix-TrenchCancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia. georgia.trench@qimrberghofer.edu.au.
Antonis C AntoniouCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. antonis@srl.cam.ac.uk.
Laura OttiniDepartment of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. laura.ottini@uniroma1.it.
Memorial Sloan Kettering Cancer Center · USNational Cancer Institute · UANational University Hospital of Iceland · ISThe University of Melbourne · AUUniversity of Copenhagen · DKCancer Research UK · GBGhent University Hospital · BEHebron University · PSPrevention Institute · USUniversity of Helsinki · FIUniversity of Pisa · ITComprehensive Cancer Center Vienna · ATGerman Cancer Research Center · DEMasaryk Memorial Cancer Institute · CZMayo Clinic · USUniversité Claude Bernard Lyon 1 · FRUniversity of Kansas Medical Center · USAristotle University of Thessaloniki · GRBeth Israel Deaconess Medical Center · USCancer Prevention Institute of California · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
Breast Cancer Family Registry CohortUM1CA164920 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI ANDRULIS, IRENE, BUYS, SAUNDRA S · 2012 to 2017
$12.7M
Variation in Hormone and xenobiotic metabolizing enzyme genes and breast cancerP50CA125183 · NCI · UNIVERSITY OF CHICAGO · PI COX, NANCY · 2006 to 2010
$11.3M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Cancer Research UK 10118Cancer Research UK 11174Cancer Research UK 15007Cancer Research UK 16563Cancer Research UK 17528Cancer Research UK C12292/A11174Cancer Research UK C1281/A12014Cancer Research UK C1287/A10118Cancer Research UK C1287/A 10710Cancer Research UK C1287/A11990Cancer Research UK C5047/A10692Cancer Research UK C5047/A15007Cancer Research UK C5047/A8384Cancer Research UK C5047/A8385Cancer Research UK C8197/A16565CIHRIntramural NIH HHSNCATS NIH HHS UL1 TR000124NCI NIH HHS 1U01CA161032NCI NIH HHS 1U19 CA148065NCI NIH HHS 1U19 CA148112NCI NIH HHS 1U19 CA148537NCI NIH HHS 5U01CA113916NCI NIH HHS CA125183NCI NIH HHS CA128978NCI NIH HHS N02 CP011019NCI NIH HHS N02 CP065504NCI NIH HHS N02-CP-11019-50NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA051008NCI NIH HHS P30 CA168524NCI NIH HHS P50 CA116201NCI NIH HHS P50 CA125183NCI NIH HHS R01 CA083855NCI NIH HHS R01-CA083855NCI NIH HHS R01 CA102776NCI NIH HHS R01-CA102776NCI NIH HHS R01 CA116167NCI NIH HHS R01 CA128978NCI NIH HHS R01 CA140323NCI NIH HHS R01CA140323NCI NIH HHS R01 CA142996NCI NIH HHS R01 CA176785NCI NIH HHS RC4 CA153828NCI NIH HHS RC4CA153828NCI NIH HHS U01 CA113916NCI NIH HHS U01 CA116167NCI NIH HHS U01 CA161032NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NCI NIH HHS UG1 CA189867NCI NIH HHS UM1 CA164920
6 · The paper itself

Abstract

backgroundBRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).

methodsWe characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.

resultsAmong BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)).

conclusionsOn the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

Indexed as

AdultAgedBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsBreast Neoplasms, MaleFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationNeoplasm StagingPolymorphism, Single NucleotideBRCA1 ProteinBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID26857456
PMCPMC4746828
OpenAlexW2264885989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.